Baraclude directly suffering from 53.55% price cuts

A hepatitis B treatment which had kept the No. 1 position in the prescription market for several years, ‘Baraclude’ is now experiencing sharp decreases in prescription in a year of its patent expiration.

It is true insurance coverage extension of its competing drug ‘Viread’ was one of the reasons which caused the trend, but the main reason was a large fall in prescription due to the large 53.5...